|
1
|
Kodama T, Takehara T, Hikita H, Shimizu S,
Li W, Miyagi T, Hosui A, Tatsumi T, Ishida H, Tadokoro S, et al:
Thrombocytopenia exacerbates cholestasis-induced liver fibrosis in
mice. Gastroenterology. 138:2498.e1–2498.e7. 2010. View Article : Google Scholar
|
|
2
|
Hernandez-Gea V and Friedman SL: Platelets
arrive at the scene of fibrosis……studies. J Hepatol. 54:1063–1065.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Djordjević J, Svorcan P, Vrinić D and
Dapcević B: Splenomegaly and thrombocytopenia in patients with
liver cirrhosis. Vojnosanit Pregl. 67:166–169. 2010.(In Serbian).
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lv Y, Han X, Gong X, Ma Q, Chang S, Wu H,
Li Y and Deng J: Grading of peripheral cytopenias caused by
nonalcoholic cirrhotic portal hypertension and its clinical
significance. Cell Biochem Biophys. 71:1141–1145. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chauffard M: A'propos de la communication
de M. Vaquez. Bull Soc mzed Hop Paris. 24:1201–1203. 1907.
|
|
6
|
Morawitz P and Denecked G: Erkrankungen
der MilzHandbuch der inneren Medizin. 4. 2nd. von Bergmann G and
Staehelin R: Springer; Berlin: pp. 217–236. 1926, (In German).
|
|
7
|
Dameshek W: Hypersplenism. Bull NY Acad
Med. 31:113–136. 1955.
|
|
8
|
Lv Y: Causes of peripheral blood
cytopenias in patients with liver cirrhosis portal hypertension and
clinical significances. Open J Endocr Metab Dis. 4:85–89. 2014.
View Article : Google Scholar
|
|
9
|
Shah SH, Hayes PC, Allan PL, Nicoll J and
Finlayson ND: Measurement of spleen size and its relation to
hypersplenism and portal hemodynamics in portal hypertension due to
hepatic cirrhosis. Am J Gastroenterol. 91:2580–2583.
1996.PubMed/NCBI
|
|
10
|
Aster RH: Pooling of platelets in the
spleen: Role in the pathogenesis of ‘hypersplenic’
thrombocytopenia. J Clin Invest. 45:645–657. 1966. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Charrier S, Blundell M, Cédrone G, Louache
F, Vainchenker W, Thrasher AJ and Galy A: Wiskott-Aldrich syndrome
protein- deficient hematopoietic cells can be efficiently mobilized
by granulocyte colony-stimulating factor. Haematologica.
98:1300–1308. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Li ZF, Zhang Y, Gao J, Zhang PJ, Wang JX
and Liu XG: Expression and significance of Toll-like receptor 4 of
splenic macrophage in patients with hypersplenism due to portal
hypertension. Zhonghua Yi Xue Za Zhi. 84:1088–1091. 2004.(In
Chinese). PubMed/NCBI
|
|
13
|
Griffith RC and Janney CG: Hematopoiet
system: bone marrow and blood, spleen, and lymph nodesAnderson's
Pathology. Kissane JM: 9th. Mosby; St. Louis, MO: pp. 1408–1447.
1990
|
|
14
|
Jiang A, Zhang S, Li Z, Liang R, Ren S, Li
J, Pu Y and Yang J: miR-615-3p promotes the phagocytic capacity of
splenic macrophages by targeting ligand-dependent nuclear receptor
corepressor in cirrhosis-related portal hypertension. Exp Biol Med
(Maywood). 236:672–680. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ma S, Li A, Li Z, Zhang S, Jiang A, Zhang
J, Zhou R and Dang S: Study of differential expression of cytokines
between portal hypertensive hypersplenic tissue and normal splenic
tissue by protein array. Chin Arch Gen Surg. 6:455–459. 2008.(In
Chinese).
|
|
16
|
Eubank TD, Galloway M, Montague CM,
Waldman WJ and Marsh CB: M-CSF induces vascular endothelial growth
factor production and angiogenic activity from human monocytes. J
Immunol. 171:2637–2643. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ma J, Chen T, Mandelin J, Ceponis A,
Miller NE, Hukkanen M, Ma GF and Konttinen YT: Regulation of
macrophage activation. Cell Mol Life Sci. 60:2334–2346. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamashita U and Kuroda E: Regulation of
macrophage-derived chemokine (MDC, CCL22) production. Crit Rev
Immunol. 22:105–114. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vulcano M, Albanesi C, Stoppacciaro A,
Bagnati R, D'Amico G, Struyf S, Transidico P, Bonecchi R, Del Prete
A, Allavena P, et al: Dendritic cells as a major source of
macrophage-derived chemokine/CCL22 in vitro and in vivo. Eur J
Immunol. 31:812–822. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lin SD, Kawakami T, Ushio A, Sato A, Sato
S, Iwai M, Endo R, Takikawa Y and Suzuki K: Ratio of circulating
follistatin and activin A reflects the severity of acute liver
injury and prognosis in patients with acute liver failure. J
Gastroenterol Hepatol. 21:374–380. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Brugger W, Möcklin W, Heimfeld S, Berenson
RJ, Mertelsmann R and Kanz L: Ex vivo expansion of enriched
peripheral blood CD34+ progenitor cells by stem cell factor,
interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and
erythropoietin. Blood. 81:2579–2584. 1993.PubMed/NCBI
|
|
22
|
Yan F, Li W, Chen JT, Zeng YM, Guo YW,
Zhang FR and Li ZF: cDNA microarray-based screening of
differentially expressed genes in macrophages in the spleen of
patients with portal hypertension and hypersplenism. Nan Fang Yi Ke
Da Xue Xue Bao. 26:1548–1551. 2006.(In Chinese). PubMed/NCBI
|
|
23
|
Yamada M, Sato N, Taniyama C, Ohtani K,
Arai K and Masai H: A 63-base pair DNA segment containing an Sp1
site but not a canonical E2F site can confer growth-dependent and
E2F-mediated transcriptional stimulation of the human ASK gene
encoding the regulatory subunit for human Cdc7-related kinase. J
Biol Chem. 277:27668–27681. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Friedman LS: The risk of surgery in
patients with liver disease. Hepatology. 29:1617–1623. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kajihara M, Kato S, Okazaki Y, Kawakami Y,
Ishii H, Ikeda Y and Kuwana M: A role of autoantibody-mediated
platelet destruction in thrombocytopenia in patients with
cirrhosis. Hepatology. 37:1267–1276. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pereira J, Accatino L, Alfaro J, Brahm J,
Hidalgo P and Mezzano D: Platelet autoantibodies in patients with
chronic liver disease. Am J Hematol. 50:173–178. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zucker ML, Hagedorn CH, Murphy CA, Stanley
S, Reid KJ and Skikne BS: Mechanism of thrombocytopenia in chronic
hepatitis C as evaluated by the immature platelet fraction. Int J
Lab Hematol. 34:525–532. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Eissa LA, Gad LS, Rabie AM and El-Gayar
AM: Thrombopoietin level in patients with chronic liver diseases.
Ann Hepatol. 7:235–244. 2008.PubMed/NCBI
|
|
29
|
Dusheiko G: Thrombopoietin agonists for
the treatment of thrombocytopenia in liver disease and hepatitis C.
Clin Liver Dis. 13:487–501. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sanjo A, Satoi J, Ohnishi A, Maruno J,
Fukata M and Suzuki N: Role of elevated platelet-associated
immunoglobulin G and hypersplenism in thrombocytopenia of chronic
liver diseases. J Gastroenterol Hepatol. 18:638–644. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Rios R, Sangro B, Herrero I, Quiroga J and
Prieto J: The role of thrombopoietin in the thrombocytopenia of
patients with liver cirrhosis. Am J Gastroenterol. 100:1311–1316.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Lv YF, Li XQ, Gong XG, Xie XH, Han XY and
Wang BC: Effect of surgery treatment on hypersplenism caused by
cirrhotic portal hypertension. Minerva Chir. 68:409–413.
2013.PubMed/NCBI
|
|
33
|
Jäger A and Kuchroo VK: Effector and
regulatory T-cell subsets in autoimmunity and tissue inflammation.
Scand J Immunol. 72:173–184. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Stein SF and Harker LA: Kinetic and
functional studies of platelets, fibrinogen, and plasminogen in
patients with hepatic cirrhosis. J Lab Clin Med. 99:217–230.
1982.PubMed/NCBI
|
|
35
|
Ikura Y, Ohsawa M, Okada M, Iwai Y and
Wakasa K: The significance of platelet consumption in the
development of thrombocytopenia in patients with cirrhosis. Am J
Med Sci. 346:199–203. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Kalambokis G and Tsianos EV: Endotoxaemia
in the pathogenesis of cytopenias in liver cirrhosis Could oral
antibiotics raise blood counts? Med Hypotheses. 76:105–109. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Zuchini R, Huang CH, Tsai HW, Huang SC,
Lin CP, Chen CY, Lee GB and Lin XZ: Electromagnetic thermoablation
to treat thrombocytopenia in cirrhotic and hypersplenic rats. J
Gastroenterol Hepatol. 25:1578–1586. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chernykh ER, Starostina NM, Paltsev AI,
Leplina OY, Shevela EY, Shipunov MV, Selihova YB, Kulagin AD,
Lisukov IA, Nikonov SD, et al: Autologous bone marrow cells in the
treatment of cirrhosis of the liver. Bull Exp Biol Med.
144:640–645. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhang W, Zhang S, Li ZF, Huang C, Ren S,
Zhou R, Jiang A and Yang AN: Knockdown of PIK3R1 by shRNA inhibits
the activity of the splenic macrophages associated with
hypersplenism due to portal hypertension. Pathol Res Pract.
206:760–767. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kenawi MM, el-Ghamrawi KA, Mohammad AA,
Kenawi A and el-Sadek AZ: Splenic irradiation for the treatment of
hypersplenism from congestive splenomegaly. Br J Surg. 84:860–861.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ismail E, Abdelmoety H, Elgerby MM and
Abden H: Splenic irradiation in the treatment of hypersplenism from
congestive splenomegaly. Life Sci J. 9:1121–1126. 2012.
|
|
42
|
Feng Kai, Ma K-S and Dong J-H: Changes of
serum Tuftsin content among hypersplenism patients before and after
radiofrequency ablation or splenectomy. Acta Academiae Medicinae
Militaris Tertiae. 28:1983–1985. 2006.(In Chinese).
|
|
43
|
Spigos DG, Jonasson O, Mozes M and Capek
V: Partial splenic embolization in the treatment of hypersplenism.
AJR Am J Roentgenol. 132:777–782. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Sankararaman S, Velayuthan S, Vea R and
Herbst J: Severe gastric variceal bleeding successfully treated by
emergency splenic artery embolization. Pediatr Int. 55:e42–e45.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
He XH, Li WT, Peng WJ, Li GD, Wang SP and
Xu LC: Total embolization of the main splenic artery as a
supplemental treatment modality for hypersplenism. World J
Gastroenterol. 17:2953–2957. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Krishnan SK, Hill A, Hillmen P, Arnold LM,
Brooksbank GL, Wood A, Scarsbrook A, Davies MH and Kelly RJ:
Improving cytopenia with splenic artery embolization in a patient
with paroxysmal nocturnal hemoglobinuria on eculizumab. Int J
Hematol. 98:716–718. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
N'Kontchou G, Seror O, Bourcier V, Mohand
D, Ajavon Y, Castera L, Grando-Lemaire V, Ganne-Carrie N, Sellier
N, Trinchet JC, et al: Partial splenic embolization in patients
with cirrhosis: efficacy, tolerance and long-term outcome in 32
patients. Eur J Gastroenterol Hepatol. 17:179–184. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Kim H, Suh KS, Jeon YM, Park MS, Choi Y,
Mori S, Hong G, Lee HW, Yi NJ and Lee KW: Partial splenic artery
embolization for thrombocytopenia and uncontrolled massive ascites
after liver transplantation. Transplant Proc. 44:755–756. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Lv Y, Gong X, Xie X, Wang B, Yang Y and Li
Y: Clinical study on the relationship between hematocytopenia and
splenomegaly caused by cirrhotic portal hypertension. Cell Biochem
Biophys. 70:355–360. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Yoshida D, Nagao Y, Tomikawa M, Kawanaka
H, Akahoshi T, Kinjo N, Uehara H, Hashimoto N, Hashizume M and
Maehara Y: Predictive factors for platelet count after laparoscopic
splenectomy in cirrhotic patients. Hepatol Int. 6:657–661. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Ushitora Y, Tashiro H, Takahashi S, Amano
H, Oshita A, Kobayashi T, Chayama K and Ohdan H: Splenectomy in
chronic hepatic disorders: portal vein thrombosis and improvement
of liver function. Dig Surg. 28:9–14. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Zhan XL, Ji Y and Wang YD: Laparoscopic
splenectomy for hypersplenism secondary to liver cirrhosis and
portal hypertension. World J Gastroenterol. 20:5794–5800. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Tomikawa M, Akahoshi T, Sugimachi K, Ikeda
Y, Yoshida K, Tanabe Y, Kawanaka H, Takenaka K, Hashizume M and
Maehara Y: Laparoscopic splenectomy may be a superior supportive
intervention for cirrhotic patients with hypersplenism. J
Gastroenterol Hepatol. 25:397–402. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Inagaki Y, Sugimoto K, Shiraki K, Tameda
M, Kusagawa S, Nojiri K, Ogura S, Yamamoto N, Takei Y, Ito M, et
al: The long-term effects of splenectomy and subsequent interferon
therapy in patients with HCV-related liver cirrhosis. Mol Med Rep.
9:487–492. 2014.PubMed/NCBI
|
|
55
|
Ishigami M, Ishizu Y, Onishi Y, Kamei H,
Kiuchi T, Itoh A, Hirooka Y, Katano Y and Goto H: Long-term
dynamics of hematological data and spleen volume in cirrhotic
patients after liver transplantation-various dynamics depending on
etiology. Springerplus. 2:3742013. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Chu HC, Hsieh CB, Hsu KF, Fan HL, Hsieh TY
and Chen TW: Simultaneous splenectomy during liver transplantation
augments anti-viral therapy in patients infected with hepatitis C
virus. Am J Surg. 209:180–186. 2015. View Article : Google Scholar : PubMed/NCBI
|
